Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The conversation is about a potential new hair loss treatment called Breezula CB-03-01. Users are discussing updates on its development and sharing personal experiences with making or using it.

Intradermal botulinum toxin (BTX) injections effectively treat androgenetic alopecia (AGA) by inhibiting TGF-β1 secretion from hair follicles. Further research and long-term follow-up are needed to confirm these findings.

The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

The user is using a hair loss treatment regimen that includes applying various topical solutions and taking oral medication. They are mixing their topical treatments to save time but are concerned about the effectiveness of the treatments when combined and stored.

The conversation is about a person considering participating in a study for Clascoterone, a topical cream for hair loss, and seeking advice on potential side effects. They have mild hair loss and are not currently using other treatments like finasteride.

The user underwent a hair transplant in Boston, initially dissatisfied with the results, but later achieved significant improvement in hair density and natural appearance after consulting a different surgeon. They used finasteride, minoxidil, and low-level laser therapy as part of their treatment.

The user experienced hair regrowth with oral minoxidil and finasteride but faced aggressive hair loss after developing IBS, questioning if the condition affects medication absorption. They are considering switching to topical treatments.

Taurine shows potential in combating hair loss caused by chemical stress, especially when combined with other treatments like finasteride. Finasteride demonstrated better stress-reducing effects in the study.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

The user is seeking advice on improving their hair loss treatment regimen, considering changes to their topical solution, and is curious about others' daily routines and recommendations for medications and supplements. They are contemplating switching Tretinoin for Tazarotene, Latanoprost for Bimatoprost, and possibly adding Alfatradiol, Topical Melatonin, or a topical androgen receptor antagonist.

Probiotics like L. reuteri ATCC PTA 6475 and B. longum BB536 may improve hair growth and density by reducing inflammation and reversing DHT damage. The user is trialing these probiotics personally, ordering them from the U.S. to Canada, and plans to continue if no adverse effects occur.

The conversation is about receiving a shipment of Koshine, also known as Kintor, which is an anti-androgen treatment for hair loss. The user is eager to try the KX-826 product and observe its effects and any side effects.

Trans women discuss using finasteride and dutasteride for hair loss and whether to continue after testosterone suppression. One user reduced dutasteride dosage after achieving undetectable testosterone levels.

OrganTech is working on regenerating hair and teeth, with positive results in mice, but skepticism remains about progress for humans. Users express frustration over the lack of advancements in human hair loss treatments, despite ongoing research and trials.

The user is using dutasteride, oral minoxidil, and topical minoxidil with tretinoin for hair loss. They are considering whether to continue this treatment or opt for a hair transplant for their temples.

SCUBE3 clinical trials for hair loss treatment to start this year. Treatment may involve regular, painless scalp injections to maintain hair growth.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

The conversation is about experiencing hyper-trichosis from taking oral Castor Oil. The user reports increased hair growth on the stomach and legs but is not concerned as it is harmless and will stop when the treatment stops.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

The conversation discusses GT20029 as a potential hair loss treatment that could act like a cure by targeting androgen receptors in scalp hair follicles. Specific treatments mentioned include GT20029, with a user expressing hope that it could make male pattern baldness obsolete.

Hair loss without a white bulb may indicate mechanical damage, anagen effluvium, alopecia areata, or traction alopecia. Seeking a specialist is recommended, but access can be difficult in smaller areas.

The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

The conversation is about the progress of clinical trials for SCUBE3, a potential hair loss treatment. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The FDA warned that topical finasteride can cause serious side effects like sexual dysfunction and brain fog, similar to oral finasteride. Compounded topical formulations pose additional risks due to lack of regulation.